



MEDIGARD LIMITED
Suite 14, 30 Tedder Avenue, Main Beach QLD 4217 Australia
Telephone +61 7 5578 7822; Fax +61 7 5528 4459
E-mail: office@medigard.com.au www.medigard.com.au
ABN 49 090 003 044

19 December 2017

ASX ANNOUNCEMENT

Medigard forms a Scientific and Medical Advisory Panel

Medigard Ltd (“the Company”) is pleased to announce the formation of a Scientific and Medical Advisory Panel (SMAP), initially chaired by Medigard’s Executive Director Dr Ian Dixon, to review opportunities in the development of new and innovative syringe-based technologies that will build future value in Medigard.

The SMAP’s first task will be to review the current status of acellular and synthetic biologically active materials that may be delivered via pre-filled syringes to treat a variety of health and medical conditions, potentially including age-related macular degeneration (AMD), tendinopathy, and osteoarthritis, problems being actively investigated by a number of leading Australian researchers known to Dr Dixon.

Concurrent with this review, Medigard will continue the development of its syringe technology, in partnership with Sol-Millennium, to ensure the safe and cost-effective delivery of such biologically active materials.

This move represents a further step in Medigard’s ambition to derive revenue and profit from advanced products, including pre-filled syringes, that have improved margins and commercial prospects.

PATRICIA BOERO
(Company Secretary)